Review synthesizes molecular pathways and targeted treatments in immune-mediated skin diseases, highlighting a shift toward individualized therapies like JAK inhibitors.
Immune-mediated skin diseases (IMSDs) comprise a heterogeneous group of chronic inflammatory dermatoses driven by dysregulated immune activation and characterized by diverse clinical phenotypes, prolonged or relapsing disease courses, and frequent systemic involvement. Advances in the understanding of key inflammatory pathways, particularly the IL-17/23 and JAK/STAT signaling axes, have transformed therapeutic paradigms from broad immunosuppression toward mechanism-based targeted interventions, including JAK inhibitors. This review systematically summarizes the classification, molecular pathogenesis, comorbidity burden, and evolving therapeutic landscape of IMSDs, providing an integrated framework to support clinical diagnosis, disease stratification, and individualized management.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: